Estudo de coorte | Adicionar um novo anti-hipertensivo a regimes já existentes está associado a maiores reduções na pressão arterial do que o aumento da dose do medicamento inicial.

Adding a New Medication Versus Maximizing Dose to Intensify Hypertension Treatment in Older Adults: A Prospective Observational Study – Annals of Internal Medicine

Comunicado de imprensa: When blood pressure needs more control, what’s better: An additional drug or more of the same? – Michigan Medicine

Comentário: Adding an antihypertensive to existing regimens associated with greater BP reduction than maximizing dose, with some caveats in adherence – ACP Internist

Conteúdo relacionado: #ESCCongress – RCT: Initial hypertension treatment with a single pill with 4 drugs at quarter doses (irbesartan 37.5 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg) achieved better BP lowering vs. standard monotherapy (irbesartan 150 mg).

Comentário no Twitter (fio – clique para saber mais)

Excited to see our paper in Annals today looking at blood pressure control regiments by adding multiple low dose meds vs. maxing dose then starting new meds. 🧵 https://t.co/3d4L2nZO4v

— Jeremy Sussman (@JeremySussman) October 5, 2021